Transplant outcomes in study population
| Outcome of interest . | Estimate (95% CI) . |
|---|---|
| PRG | |
| 1 y | 48% (42-54) |
| 2 y | 53% (46-60) |
| NRM | |
| 1 y | 21% (17-27) |
| 2 y | 22% (18-29) |
| OS | |
| 1 y | 41% (35-48) |
| 2 y | 29% (23-36) |
| PFS | |
| 1 y | 30% (25-37) |
| 2 y | 24% (19-30) |
| Grades 2-4 aGVHD | |
| 3 mo | 39% (33-46) |
| 6 mo | 42% (36-48) |
| Grades 3-4 aGVHD | |
| 3 mo | 6% (3-10) |
| 6 mo | 7% (4-11) |
| Chronic GVHD | |
| 1 y | 8% (5-12) |
| 2 y | 12% (8-17) |
| Outcome of interest . | Estimate (95% CI) . |
|---|---|
| PRG | |
| 1 y | 48% (42-54) |
| 2 y | 53% (46-60) |
| NRM | |
| 1 y | 21% (17-27) |
| 2 y | 22% (18-29) |
| OS | |
| 1 y | 41% (35-48) |
| 2 y | 29% (23-36) |
| PFS | |
| 1 y | 30% (25-37) |
| 2 y | 24% (19-30) |
| Grades 2-4 aGVHD | |
| 3 mo | 39% (33-46) |
| 6 mo | 42% (36-48) |
| Grades 3-4 aGVHD | |
| 3 mo | 6% (3-10) |
| 6 mo | 7% (4-11) |
| Chronic GVHD | |
| 1 y | 8% (5-12) |
| 2 y | 12% (8-17) |
aGVHD, acute graft-versus-host disease; PRG, disease progression.